BRPI0414594A - derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases - Google Patents
derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinasesInfo
- Publication number
- BRPI0414594A BRPI0414594A BRPI0414594-1A BRPI0414594A BRPI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A BR PI0414594 A BRPI0414594 A BR PI0414594A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- diseases
- acid derivatives
- imino acid
- ring
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 102000005741 Metalloproteases Human genes 0.000 title 1
- 108010006035 Metalloproteases Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 208000036487 Arthropathies Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 abstract 1
- -1 IMINO Chemical class 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010065433 Ligament rupture Diseases 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000003041 ligament Anatomy 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000004417 patella Anatomy 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADOS DE IMINOáCIDOS BICìCLICOS COMO INIBIDORES DE MATRIZ DE METALOPROTEINASES". A presente invenção refere-se a compostos da Fórmula (I) Legendas da tabela 1: ring = anel que são apropriados para a preparação de medicamentos para a profilaxia e terapia de doenças, de cujo curso toma parte uma atividade reforçada da matriz de metaloproteinases. Doenças pertencentes a estas são doenças degenerativas das articulações, como por exemplo osteoartroses, espondiloses, lesão dos ligamentos após trauma nas articulações ou após imobilização da articulação depois de maiores lesões no menisco ou na patela ou rupturas dos ligamentos, ou uma doença do tecido conectivo como colagenose, doenças periodontais, distúrbios de cicatrização, ou uma doença crónica do sistema locomotor tal como artrite, aguda ou crónica, artropatias, mialgias, ou perturbações do metabolismo ósseo ou uma ulceração, ateroesclerose, ou estenose ou uma doença inflamatória, ou câncer, formação de metástase tumoral, caquexia, anorexia ou choque séptico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (de) | 2003-09-27 | 2003-09-27 | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
| PCT/EP2004/010248 WO2005030728A1 (de) | 2003-09-27 | 2004-09-14 | Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414594A true BRPI0414594A (pt) | 2006-11-07 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414594-1A BRPI0414594A (pt) | 2003-09-27 | 2004-09-14 | derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (pt) |
| JP (1) | JP4861179B2 (pt) |
| KR (1) | KR20060086367A (pt) |
| CN (1) | CN1856478B (pt) |
| AR (1) | AR046165A1 (pt) |
| AT (1) | ATE550327T1 (pt) |
| AU (1) | AU2004275937A1 (pt) |
| BR (1) | BRPI0414594A (pt) |
| CA (1) | CA2539731A1 (pt) |
| DE (1) | DE10344936A1 (pt) |
| IL (1) | IL174040A0 (pt) |
| MA (1) | MA28075A1 (pt) |
| ME (1) | MEP33008A (pt) |
| MX (1) | MXPA06002927A (pt) |
| MY (1) | MY139830A (pt) |
| NO (1) | NO20061837L (pt) |
| NZ (1) | NZ546158A (pt) |
| PE (1) | PE20050432A1 (pt) |
| RS (1) | RS20060194A (pt) |
| RU (1) | RU2335494C2 (pt) |
| TW (1) | TW200520755A (pt) |
| UY (1) | UY28539A1 (pt) |
| WO (1) | WO2005030728A1 (pt) |
| ZA (1) | ZA200601501B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
| DE102005002500A1 (de) | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (pt) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (fr) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| US6207672B1 (en) * | 1995-11-13 | 2001-03-27 | Aventis Pharma Deutschland Gmbh | Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids |
| KR100339296B1 (ko) * | 1996-08-28 | 2002-06-03 | 데이비드 엠 모이어 | 헤테로고리성 메탈로프로테아제 억제제 |
| PL334846A1 (en) * | 1997-01-23 | 2000-03-27 | Hoffmann La Roche | Sulphamidic inhibitors of metaloproteases |
| DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
| DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/de not_active Withdrawn
-
2004
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/de not_active Ceased
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/xx unknown
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/sr unknown
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/ko not_active Ceased
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/zh not_active Expired - Fee Related
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/ja not_active Expired - Fee Related
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/pt not_active IP Right Cessation
- 2004-09-14 AT AT04786944T patent/ATE550327T1/de active
- 2004-09-14 EP EP04786944A patent/EP1670766B1/de not_active Expired - Lifetime
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/ru not_active IP Right Cessation
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/es active IP Right Grant
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/es not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/zh unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/es not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/es unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/fr unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY139830A (en) | 2009-10-30 |
| TW200520755A (en) | 2005-07-01 |
| AR046165A1 (es) | 2005-11-30 |
| UY28539A1 (es) | 2005-04-29 |
| EP1670766B1 (de) | 2012-03-21 |
| NO20061837L (no) | 2006-06-01 |
| RU2006114352A (ru) | 2006-08-27 |
| KR20060086367A (ko) | 2006-07-31 |
| NZ546158A (en) | 2008-11-28 |
| RU2335494C2 (ru) | 2008-10-10 |
| WO2005030728A1 (de) | 2005-04-07 |
| CA2539731A1 (en) | 2005-04-07 |
| JP4861179B2 (ja) | 2012-01-25 |
| DE10344936A1 (de) | 2005-04-21 |
| RS20060194A (sr) | 2008-08-07 |
| ZA200601501B (en) | 2007-04-25 |
| PE20050432A1 (es) | 2005-07-21 |
| JP2007506690A (ja) | 2007-03-22 |
| EP1670766A1 (de) | 2006-06-21 |
| ATE550327T1 (de) | 2012-04-15 |
| MEP33008A (en) | 2010-10-10 |
| IL174040A0 (en) | 2006-08-01 |
| MXPA06002927A (es) | 2006-06-14 |
| CN1856478A (zh) | 2006-11-01 |
| AU2004275937A1 (en) | 2005-04-07 |
| CN1856478B (zh) | 2010-05-26 |
| MA28075A1 (fr) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407919A (pt) | pirrolopirimidinas espiro-substituìdas | |
| BRPI0413616B1 (pt) | 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica | |
| Zeng et al. | Icariin inhibits MMP‑1, MMP‑3 and MMP‑13 expression through MAPK pathways in IL‑1β‑stimulated SW1353 chondrosarcoma cells | |
| WO2018226732A1 (en) | Multibiotic agents and methods of using the same | |
| BRPI0509340A (pt) | formulação compreendendo inibidores de histona desacetilase | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| BRPI0413490A (pt) | novos compostos | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| ITMI20031311A1 (it) | Formulazioni per il trattamento di disturbi artrosici. | |
| BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
| WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| BR0313384A (pt) | Derivados de cromona como inibidores de metaloproteinases de matriz | |
| BRPI0414594A (pt) | derivados de iminoácidos bicìclicos como inibidores de matriz de metaloproteinases | |
| BR112013030874B8 (pt) | Uso de uma theta-defensina ou análogo da mesma para tratar uma condição inflamatória crônica | |
| BR0111202A (pt) | Compostos de tienodibenzoazuleno como inibidores do fator de necrose tumoral | |
| PT1124841E (pt) | Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem | |
| BR0115306A (pt) | Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico | |
| WO2005073236A3 (de) | Thieno-iminosäure-derivate als inhibitoren von matrix-metalloproteinasen | |
| BR0317834A (pt) | Diamidas de ácido pirimidin-4,6-dicarboxìlico como inibidores mmp 13 seletivos | |
| BR0308088A (pt) | ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase | |
| BRPI0606493A2 (pt) | derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz | |
| CL2004000810A1 (es) | Compuesto derivado de acido hidroxamico de formula definida; composicion farmaceutica que comprende al compuesto y uso del compuesto para preparar medicamentos utiles para tratar trastornos hiperproliferativos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |